VERIFIEDET Stocks·8 Sept 2026positive

Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil

AI Summary

·Biocon shares increased by 2% following a 10-year supply agreement for Pertuzumab in Brazil.
·The company, in a consortium with Bahiafarma and Bionovis, secured full allocation under Brazil's PDP programme.
·This agreement will provide access to approximately 70% of the public-sector demand for the breast cancer therapy.